Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): a multicentre, double-blind, randomised controlled trial

Hof, Arnoud Wj van’t; Berg, Jurriën Ten; Heestermans, Ton; Dill, Thorsten; Funck, R.; Werkum, Wouter van; Dambrink, Jan‐Henk E.; Suryapranata, Harry; Houwelingen, Gert van; Ottervanger, Jan Paul; Stella, Pieter R.; Giannitsis, Evangelos; Hamm, Christian W.

doi:10.1016/s0140-6736(08)61235-0

Cited by 439 publications

(310 citation statements)

References 37 publications

Supporting

Mentioning

288

Contrasting

Unclassified

Order By: Relevance

“…However, more recently high-dose bolus of tirofiban and double bolus of eptifibatide have been shown to provide more complete and faster inhibition of platelet aggregation and therefore larger benefits would be expected from these new dosages. The on-time-2 trial [44] investigated the benefits from early highdose tirofiban administration in the ambulance as compared to placebo, with significant benefits in preprocedural recanalization and STresolution. When the data were pooled with the pilot phase, there was a significant reduction in mortality.…”

Section: Discussionmentioning

confidence: 99%

Time-to-treatment and infarct size in STEMI patients undergoing primary angioplasty

Luca¹,

Parodi

Sciagrà

et al. 2013

International Journal of Cardiology

View full text Add to dashboard Cite

Background: Several reports have shown that in patient with ST-segment elevation acute myocardial infarction (STEMI) longer ischemia time is associated with impaired reperfusion and higher mortality. However, there is still some doubts with regards time to reperfusion role in patients treated with primary percutaneous coronary intervention (PCI). Therefore, the aim of the current study was to evaluate the impact of time-totreatment on infarct size as evaluated by myocardial scintigraphy in a large cohort of STEMI patients undergoing primary PCI. Methods: Our population is represented by 830 STEMI patients undergoing primary PCI. Infarct size was evaluated at 30 days by technetium-99m-sestamibi. Conclusions: This study shows in a large population of STEMI patients undergoing primary PCI that time-totreatment is linearly associated with infarct size.

show abstract

Section: Discussionmentioning

confidence: 99%

Time-to-treatment and infarct size in STEMI patients undergoing primary angioplasty

Luca¹,

Parodi

Sciagrà

et al. 2013

International Journal of Cardiology

View full text Add to dashboard Cite

show abstract

“…12 Patients receiving high-dose tirofiban (25 mcg/ kg bolus followed by 0.15 mcg/kg per min for 18 hours) at first medical contact before transport for primary PCI were also treated with unfractionated heparin (UFH; 5000 U), clopidogrel (600 mg), and ASA. Patients in the high-dose tirofiban group had improved ST-segment resolution (primary end point) before and 1 hour after PCI (P¼ 0.003) compared with those receiving placebo (NNT¼ 100).…”

Section: Stemi and Pci Focused Update Sectionmentioning

confidence: 99%

2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST‐Elevation Myocardial Infarction (Updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (Updating the 2005 Guideline and 2007 Focused Update)

Kushner¹,

Hand

Smith³

et al. 2009

Cathet Cardio Intervent

113

102

View full text Add to dashboard Cite

“…2 In the OASIS 5 and 6 trials treatment with fondaparinux alone led to an increase of catheter thrombosis during coronary catheterisation procedures. 16,17 Therefore, when deciding on an invasive approach, unfractionated heparin should be added to the antithrombotic therapy to prevent catheter thrombosis. The OASIS 5 and 6 trials showed improved survival explained by a reduction in bleeding complications.…”

Section: Ua/nstemimentioning

confidence: 99%

Guideline adherence for antithrombotic therapy in acute coronary syndrome: an overview in Dutch hospitals

Kikkert

Piek²,

Winter³

et al. 2010

NHJL

View full text Add to dashboard Cite

Objective. To assess current Dutch antithrombotic treatment strategies for acute coronary syndrome (ACS) in light of the current European Society of Cardiology (ESC) guidelines. Methods. For every Dutch hospital with a coronary care unit (CCU) (n = 93) a single cardiologist was interviewed concerning heparin, thienopyridine and GP IIb/IIIa inhibitor (GPI) treatment. In each hospital, we randomly approached one cardiologist assuming equal policy among physicians employed at the same hospital.

show abstract

Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): a multicentre, double-blind, randomised controlled trial

Cited by 439 publications

References 37 publications

Time-to-treatment and infarct size in STEMI patients undergoing primary angioplasty

Time-to-treatment and infarct size in STEMI patients undergoing primary angioplasty

2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST‐Elevation Myocardial Infarction (Updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (Updating the 2005 Guideline and 2007 Focused Update)

Guideline adherence for antithrombotic therapy in acute coronary syndrome: an overview in Dutch hospitals

Contact Info

Product

Resources

About